Cargando…

The changing face of acute myeloid leukemia therapeutics in the elderly population

Detalles Bibliográficos
Autores principales:	Daver, Naval, Cortes, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382773/ https://www.ncbi.nlm.nih.gov/pubmed/25839008 http://dx.doi.org/10.4103/2278-330X.149900

Ejemplares similares

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2019)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

New directions for emerging therapies in acute myeloid leukemia: the next chapter
por: Daver, Naval, et al.
Publicado: (2020)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Extramedullary Acute Myeloid Leukemia: Leukemic Pleural Effusion, Case Report and Review of the Literature
por: Pemmaraju, Naveen, et al.
Publicado: (2014)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Determination of fitness and therapeutic options in older patients with acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2021)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
por: Samra, Bachar, et al.
Publicado: (2020)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

miRNAs as prognostic predictors in acute myeloid leukemia
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
por: Daver, Naval, et al.
Publicado: (2020)

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
por: McCall, David, et al.
Publicado: (2021)

Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
por: Thol, Felicitas
Publicado: (2022)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Current treatment for pediatric acute myeloid leukemia
por: Im, Ho Joon
Publicado: (2018)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Pulling the Pin on NPMc(+) acute myeloid leukemia
por: Kats, Lev M.
Publicado: (2021)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
por: Reville, Patrick K., et al.
Publicado: (2021)

Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions
por: Lanza, Francesco, et al.
Publicado: (2021)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Daver, Naval G., et al.
Publicado: (2023)

NOX2: a determinant of acute myeloid leukemia survival
por: Jones, Courtney L.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ogq4h9ctbpocatugnr82fcs491